- Home
- PK vs BEAM Comparison
PK vs BEAM Comparison
Compare PK & BEAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PK
- BEAM
- Stock Information
- Founded
- PK 1946
- BEAM 2017
- Country
- PK United States
- BEAM United States
- Employees
- PK N/A
- BEAM N/A
- Industry
- PK Real Estate Investment Trusts
- BEAM Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PK Real Estate
- BEAM Health Care
- Exchange
- PK Nasdaq
- BEAM Nasdaq
- Market Cap
- PK 2.5B
- BEAM 2.3B
- IPO Year
- PK N/A
- BEAM 2020
- Fundamental
- Price
- PK $10.91
- BEAM $22.21
- Analyst Decision
- PK Buy
- BEAM Strong Buy
- Analyst Count
- PK 11
- BEAM 11
- Target Price
- PK $17.95
- BEAM $50.50
- AVG Volume (30 Days)
- PK 4.7M
- BEAM 2.3M
- Earning Date
- PK 05-05-2025
- BEAM 05-06-2025
- Dividend Yield
- PK 12.83%
- BEAM N/A
- EPS Growth
- PK 129.54
- BEAM N/A
- EPS
- PK 1.01
- BEAM N/A
- Revenue
- PK $2,611,000,000.00
- BEAM $63,518,000.00
- Revenue This Year
- PK $3.56
- BEAM N/A
- Revenue Next Year
- PK $3.55
- BEAM $6.32
- P/E Ratio
- PK $10.81
- BEAM N/A
- Revenue Growth
- PK N/A
- BEAM N/A
- 52 Week Low
- PK $10.84
- BEAM $20.84
- 52 Week High
- PK $17.87
- BEAM $35.25
- Technical
- Relative Strength Index (RSI)
- PK 34.11
- BEAM 38.64
- Support Level
- PK $10.89
- BEAM $21.60
- Resistance Level
- PK $11.65
- BEAM $24.53
- Average True Range (ATR)
- PK 0.39
- BEAM 1.64
- MACD
- PK -0.00
- BEAM -0.24
- Stochastic Oscillator
- PK 4.89
- BEAM 8.85
About PK Park Hotels & Resorts Inc.
Park Hotels & Resorts owns upper-upscale and luxury hotels with 22,711 rooms across 37 hotels in the United States. Park also has interests through joint ventures in another 2,271 rooms in three US hotels. Park was spun out of narrow-moat Hilton Worldwide Holdings at the start of 2017, so most of the company's hotels are still under Hilton brands. The company has sold all its international hotels and many of its lower-quality US hotels to focus on high-quality assets in domestic gateway markets.
About BEAM Beam Therapeutics Inc.
Beam Therapeutics Inc is a biotechnology company engaged in creating genetic medicines based on its base editing technology. This technology enables a new class of genetic medicines that targets a single base in the genome without making a double-stranded break in the DNA. The company's portfolio comprises Gene Correction, Gene Modification, Gene Activation, Gene Silencing, and Multiplex Editing. The company's pipeline programs consist of BEAM-101, ESCAPE, BEAM-302, BEAM-301, and BEAM-201.